Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TSPO | P30536 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2617919 | 0.85 | ATM (0.39) | ATMLMNATSHRTSPOALDH1A1 | |
| SCHEMBL11105046 | 0.78 | KMT2A (0.38) | TSHRALDH1A1KDM4ESMN1; SMN2SRD5A2 | |
| SCHEMBL11555149 | 0.77 | ELANE (0.45) | LMNATSHRALDH1A1KDM4ENPSR1 | |
| SCHEMBL3713600 | 0.76 | MEN1 (0.43) | LMNATSHRKDM4ERECQL | |
| SCHEMBL22833643 | 0.73 | LMNA (0.39) | LMNATSHRKDM4ESMN1; SMN2NPSR1 | |
| SCHEMBL15889048 | 0.72 | POLB (0.39) | LMNATSHRALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL23754685 | 0.71 | AOC2 (0.35) | TSHRALDH1A1KDM4E | |
| SCHEMBL13075305 | 0.71 | HTT (0.44) | ATMLMNAALDH1A1SMN1; SMN2RECQL | |
| SCHEMBL3788590 | 0.71 | CHRM5 (0.41) | LMNAALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL3719810 | 0.70 | HTT (0.46) | LMNATSHRALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9399033-B2 | Oligomer-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150366842-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS | 2015-12-24 | — | — | US | disclosed |
| US-9096517-B2 | Oligomer-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140288315-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS | 2014-09-25 | — | — | US | disclosed |
| US-8785661-B2 | Oligome-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2010132693-A2 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366842-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | HTT, PML, NOD2 | ATM 4603/4885LMNA 4479/4885TSHR 4577/4885 |
| US-20140288315-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | HTT, PML, NOD2 | ATM 4603/4885LMNA 4479/4885TSHR 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.